Zacks Investment Research Lowers Swedish Orphan Bio (SWTUY) to Hold

Zacks Investment Research cut shares of Swedish Orphan Bio (OTCMKTS:SWTUY) from a buy rating to a hold rating in a research report released on Friday.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

Swedish Orphan Bio stock opened at $17.30 on Friday. Swedish Orphan Bio has a 12-month low of $12.55 and a 12-month high of $17.60. The company has a quick ratio of 1.21, a current ratio of 1.72 and a debt-to-equity ratio of 0.08.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Swedish Orphan Bio (SWTUY) to Hold” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Swedish Orphan Bio Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren’s contracture and Peyronie’s disease.

Get a free copy of the Zacks research report on Swedish Orphan Bio (SWTUY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Swedish Orphan Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio and related companies with's FREE daily email newsletter.

Leave a Reply